If you’ve been researching weight loss or diabetes medications in Canada, you’ve probably hit the words “Mounjaro” and “Zepbound” — and maybe also “tirzepatide,” which sounds like a chemistry term that got lost on its way to a lab.
Here’s the short version: Mounjaro and Zepbound are both the same drug. That drug is called tirzepatide. It’s made by Eli Lilly. The reason there are two brand names is that Health Canada approved it twice — once for diabetes, once for weight management — and pharmaceutical companies typically brand those separately.
This page is about how tirzepatide actually works, what the clinical trials showed (in terms a person can understand), and what your realistic options are for getting it in Canada.
How Tirzepatide Works — Without the Jargon
Your gut releases hormones when you eat. Two of them — GLP-1 and GIP — are signals that tell your brain you’re satisfied, slow down your digestion, and help your body manage blood sugar. Most people produce these signals naturally, but in people with obesity or type 2 diabetes, the signalling system often doesn’t work as well as it should.
Ozempic and Wegovy (semaglutide) mimic GLP-1 only. That’s already enough to produce meaningful weight loss for most people.
Tirzepatide mimics both GLP-1 and GIP at the same time. That second hormone, GIP, works alongside GLP-1 to boost insulin secretion and appears to affect how the body stores fat. The combination is why tirzepatide generally produces more weight loss than semaglutide in clinical comparisons — you’re hitting two separate appetite and metabolism pathways instead of one.
It’s a once-weekly injection. Small needle, typically into the abdomen, thigh, or upper arm. Most people are surprised by how manageable the injection is — the dose starts very low and escalates gradually over several months, which helps your body adjust.
Mounjaro vs. Zepbound — Why There Are Two Names
Both are tirzepatide. Same drug, same doses, same manufacturer (Eli Lilly), same pens. The difference is what they’re approved for:
Mounjaro — Health Canada approved for type 2 diabetes management. If your doctor is treating your blood sugar and HbA1c, Mounjaro is the brand name on the prescription.
Zepbound — Health Canada approved for chronic weight management in adults. The eligibility criteria: BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related health condition (high blood pressure, sleep apnea, type 2 diabetes, high cholesterol, etc.).
Why does this distinction matter? Two reasons. First, it affects how your physician documents the prescription and submits for insurance coverage. Second, different manufacturer support programs apply to each (myMounjaro for Mounjaro, Lilly’s weight management program for Zepbound). Your doctor will prescribe whichever is clinically appropriate for your situation — but it’s useful to understand the logic.
What the Clinical Trials Actually Showed
The headline results for tirzepatide came from two major trial programs: SURPASS (for diabetes) and SURMOUNT (for weight management). Both were large, rigorous trials published in the New England Journal of Medicine.
On weight loss — the SURMOUNT trials: In SURMOUNT-1, participants taking the highest dose (15 mg weekly) lost an average of 20.9% of their body weight over 72 weeks. To put that in real terms: if you weigh 220 pounds, that’s roughly 46 pounds over about 17 months.
About one in three participants on the highest dose lost 25% or more of their body weight — numbers that weren’t achievable with medication before this generation of GLP-1s.
On diabetes — the SURPASS trials: Tirzepatide consistently outperformed semaglutide and other leading diabetes medications on HbA1c reduction in head-to-head trials. For people managing both blood sugar and weight, it’s become a go-to option for many Canadian physicians.
The honest caveats: Clinical trial populations are carefully selected and closely monitored. Real-world results tend to be more variable — some people respond very well, others see more modest effects. A few percent of people don’t respond meaningfully at all. The trials are genuinely compelling evidence, but they’re not a guarantee of what you’ll experience personally.
How Does It Compare to Ozempic and Generic Semaglutide?
This is the comparison most people want, so let’s do it directly.
| Tirzepatide (Mounjaro / Zepbound) | Semaglutide (Ozempic / Wegovy) | Generic Semaglutide | |
|---|---|---|---|
| Mechanism | GLP-1 + GIP dual agonist | GLP-1 agonist | GLP-1 agonist |
| Average weight loss (trials) | ~20–22% | ~12–15% | ~12–15% |
| Injection frequency | Weekly | Weekly | Weekly |
| Monthly cost (no insurance) | ~$350–$500 | ~$250–$350 | ~$100–$200 (est.) |
| Generic available in Canada | Not yet | Yes (approved 2026) | Yes |
| Coverage (diabetes) | Established with SA | Established with SA | Being established |
The simple answer: tirzepatide generally produces more weight loss. The less simple answer: “on average” covers a lot of variation, and at double or triple the cost of generic semaglutide, the right choice depends on your individual response, insurance situation, and budget.
If you’ve already tried semaglutide (Ozempic or generic) without enough response, tirzepatide is the logical next conversation with your doctor. If you’re starting fresh, this is a decision worth making with a physician who knows your full health picture.
Side Effects — What to Actually Expect
Tirzepatide’s side effects are similar to other GLP-1 medications, and they’re most noticeable when you first start or increase your dose.
Common (especially in the first few weeks): Nausea, mild stomach discomfort, changes in bowel habits — some people get diarrhea, some get constipation, many get both at different points. The good news is these tend to fade significantly after a few weeks at each dose level. The slow dose escalation schedule exists specifically to minimize this.
Less common but worth knowing about: Potential gallbladder issues. GLP-1 medications can slow gallbladder emptying, and rapid weight loss of any kind can increase gallstone risk. If you have a history of gallbladder problems, tell your doctor before starting. Mild hair thinning is also reported by some patients, typically temporary and related to the physiological effects of significant weight loss.
If you’re on insulin or sulfonylureas: The combination can lower blood sugar more than expected. Your diabetes management plan may need adjustment when you start tirzepatide — your physician will know to watch for this.
When to call your doctor right away: Severe or persistent vomiting, significant abdominal pain that doesn’t resolve, or any signs of an allergic reaction.
How to Get a Tirzepatide Prescription in Canada
You need a prescription from a licensed Canadian physician or nurse practitioner. Here are the realistic routes:
Your family doctor is the natural starting point. GLP-1 prescriptions have become common enough that most Canadian family physicians are comfortable initiating them. A conversation about your weight history, relevant health conditions, and treatment goals is usually enough to get started.
Obesity medicine or weight loss clinics are worth knowing about if your family doctor is unfamiliar with GLP-1s or if you want more specialized support. These clinics deal with this daily and can often move faster on insurance navigation.
Telehealth platforms have made GLP-1 consultations a core service in Canada. A video consultation with a Canadian physician, a prescription sent to your local pharmacy, and you’re underway — no waiting for an in-person appointment. This is particularly useful if your family doctor has a long wait time or if you’re in a rural area.
[LEAD CAPTURE FORM: Connect me with a tirzepatide provider in my area — embed here]
Cost and Coverage in Canada
Without insurance, tirzepatide runs approximately $350–$500/month depending on dose. For the full breakdown of prices by dose, insurance pathways, the myMounjaro program, and practical tips for lowering your cost — see these pages:
→ How much does Mounjaro cost in Canada? (How Much Does Mounjaro Cost in Canada? (2026 Prices + Ways to Pay Less))
→ GLP-1 savings programs for Canadians (GLP-1 Savings Programs in Canada — What’s Actually Available (And What Isn’t))
→ Is my GLP-1 covered by insurance? (Is My GLP-1 Covered by Insurance in Canada? A Straight Answer)The Questions We Hear Most
What’s the difference between Mounjaro and Zepbound in Canada? Same drug, same doses, different Health Canada indication. Mounjaro is for type 2 diabetes. Zepbound is for weight management. Your physician prescribes whichever matches your situation.
How long does it take to see results on tirzepatide? Most people notice appetite changes within the first one to two weeks. Visible weight changes typically come within the first 4–8 weeks. Significant results — 10–15% of body weight — tend to appear around the 3–6 month mark. Maximum benefit usually comes after 12–18 months of consistent use.
Is there a generic tirzepatide in Canada? Not yet. Tirzepatide is under patent by Eli Lilly. Generic versions are not expected in Canada for several years. Generic semaglutide (the Ozempic equivalent) is now available in Canada — that’s the more affordable option for people who want a semaglutide-based medication.
Can I take tirzepatide if I don’t have diabetes? Yes — that’s exactly what Zepbound is approved for. Weight management, regardless of diabetes status. Eligibility requires a BMI of 30+, or 27+ with a qualifying health condition.
Does tirzepatide cause muscle loss? Some loss of lean mass can occur with any significant weight loss. Clinical data suggests the weight lost on tirzepatide is predominantly fat. Getting enough protein and doing some resistance exercise helps protect muscle during treatment — your doctor or a registered dietitian can give specific guidance for your situation.
What happens if I stop taking tirzepatide? Like other GLP-1 medications, stopping tirzepatide typically leads to weight regain over time. The medication manages a chronic condition — obesity — rather than curing it. Many physicians approach it as a long-term treatment, similar to blood pressure or cholesterol medication.
Sources:
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022 (SURMOUNT-1)
- Frias JP, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” New England Journal of Medicine, 2021 (SURPASS-2)
- Health Canada Drug Product Database — Mounjaro and Zepbound product monographs
- Eli Lilly Canada — tirzepatide prescribing and patient support information (lilly.ca)
Last updated: May 2026 | GLP1Directory.ca This page is for informational purposes only and does not constitute medical advice. Clinical trial results represent population averages; individual outcomes vary. Speak with a licensed Canadian healthcare provider before starting or changing any medication.